Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
POINT Biopharma
Indianapolis, Indiana, United Statespoint-biopharma.webflow.io ↗
- Ownership
- Public · PNT
- Development stage
- Commercial
01
Overview
POINT Biopharma developed a pipeline of radioligand therapies targeting various cancers. Its lead asset, 177Lu-PNT2003 targeting SSTR2 for neuroendocrine tumors, reached Phase 3. Other programs include FAP-targeted agents in early clinical development and PSMA-targeted therapies in preclinical stages. The company was acquired by Eli Lilly in December 2023 to expand Lilly’s oncology portfolio into next-generation radioligand therapies[5][4].
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalRadioligand therapySmall moleculePeptide conjugate radionuclide
- Industry
- Biotech
02
Partnerships
Athebio AG – collaboration on DARPin-targeted radioligands (“Radio-DARPins”)Strategic partnerships for radio-isotope supply and manufacturing technology
Beyond the preview
Go deeper on POINT Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POINT Biopharma.